FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutics and medicine. Objects 1 and 2 are methods of treating refractory to PD-1/PD-L1 cancer in a human patient, comprising administering 400 mg of an anti-PD-1 antibody or an antigen-binding fragment thereof to the patient every six weeks and 25 mg of an anti-CTLA4 antibody or an antigen-binding fragment thereof to a patient every six weeks. Objects 3–6 are kits for treating a patient with refractory to PD-1/PD-L1 cancer, containing 400 mg of anti-PD-1-antibody or its antigen-binding fragment and 25 mg of an anti-CTLA4 antibody or an antigen-binding fragment thereof, a composition for treating PD-1/PD-L1 refractory cancer, and use thereof for treating an individual suffering PD-1/PD-L1 refractory cancer. Objects 7 and 8: use in combination of anti-PD-1-antibody or an antigen-binding fragment thereof in amount of 25 mg and an anti-CTLA4 antibody or an antigen-binding fragment thereof in amount of 400 mg for treating PD-1/PD-L1 refractory cancer.
EFFECT: safe and effective dosing regimen of anti-PD-1-antibody or its antigen-binding fragment and anti-CTLA4-antibody or its antigen-binding fragment.
32 cl, 4 dwg, 9 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | 2019 |
|
RU2795457C2 |
| ANTI-TNFRSF25 ANTIBODIES | 2017 |
|
RU2746314C2 |
| ANTI-PD-1 ANTIBODY | 2015 |
|
RU2722212C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
